ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’
Ardelyx Inc. (ARDX) shares rose 2% after-hours, reaffirming 2026 guidance for IBSRELA and XPHOZAH, targeting $500M+ revenue this year. The company expects $1B IBSRELA sales by 2029 and $750M peak for XPHOZAH. Profitability is anticipated soon, with operating expenses guided at $520M. Analysts rate ARDX 'Buy' with a 12-month average price target of $16.33, implying over 200% upside.
How this was made
The 30-second read
Why it matters
Guidance reaffirmation provides fresh data for valuation models.
Market read
New guidance may drive short‑term price movement and influence sector sentiment.
What to watch
Potential competitive pressure from emerging IBS treatments not discussed.
Background
Ardelyx presented guidance at the Jefferies Global Healthcare Conference.
Ticker impact
Ardelyx reiterated 2026 revenue guidance for IBSRELA and XPHOZAH, confirming combined $500M target and profitability outlook.
Potential modest upside in after‑hours trading; price may test $16‑$18 range.
New revenue numbers and profitability comment are fresh primary data, influencing valuation.
Market effects
Reinforces strength of the specialty pharma/renal‑therapy segment.
U.S. biotech sector may see modest lift as guidance beats expectations.
Limited to investors tracking US biotech earnings.
Counterpoint
Higher operating expense guidance could compress margins, limiting upside.
Key entities
- companyArdelyx Inc.
Biopharma focused on IBSRELA and XPHOZAH.
- executiveSue Hohenleitner
Chief Financial Officer of Ardelyx.
